Why is the Polynovo share price rising while other ASX 200 stocks are plummeting?

Polynovo shares are avoiding today’s market sell-off.

| More on:
A smug young man points to his chest feeling proud that he invested in Polynovo shares which are rising today amid a market sell-off

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Polynovo shares are up today amid a widespread market sell-off 
  • There have been no announcements from the company today
  • Recent insider buying action might be buoying investor sentiment 

Despite most ASX companies being in the red today, the Polynovo Ltd (ASX: PNV) share price is rising.

During late afternoon trade, the medical device company’s shares are changing hands for $1.21, up 4.76%.

In comparison, the S&P/ASX 200 Index (ASX: XJO) is plummeting by 4.33% to 6,631 points.

Polynovo defies ASX market sell-off

Polynovo investors are shrugging off the wider market slump today.

The company hasn’t made any price-sensitive announcements since its third quarter trading update in early April.

However, insider buying action among senior Polynovo managers has likely propped up the share price and overall sentiment.

In particular, Polynovo chairperson David Williams made a series of purchases from the start of May totalling more than $5 million.

Not only did Williams take advantage of the share price weakness but he’s been averaging down his cost position.

In total, Williams now has more than 24.59 million Polynovo shares spread across a series of portfolios.

The number of buy-ins conducted tells us that Williams believes the company’s shares are trading at an attractive price. This seems to have resonated with investors, which could be why Polynovo is defying the ASX sell-off today.

It is worth nothing that at the start of May, Polynovo shares hit a 52-week low of 83.5 cents.

Polynovo share price summary

Since this time last year, the Polynovo share price has fallen by 56%.

Year-to-date it has fared better, but you’d still be looking at a loss of 25% if you invested at the start of 2022.

Based on today’s share price, Polynovo presides a market capitalisation of approximately $764.25 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Why this broker sees plenty of upside for the ResMed share price

ResMed shares could be in the buy zone...

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

Looking to buy CSL shares? Here’s what to watch when the biotech company reports this week

Here’s what might be around the corner for CSL this earnings season.

Read more »

A scientist examining test results.
Healthcare Shares

Why did the Opthea share price dive 9% on Monday?

The biopharmaceutical company has announced new share issue arrangements.

Read more »

A disappointed female investor sits in front of her laptop and puts her hand to her forehead and closes her eyes in disappointment over share price falls
Capital Raising

Paradigm Biopharmaceuticals share price freefalls 27% following $66m cap raise

Paradigm shares have erased all of last week's gains...

Read more »

A woman stands facing a set of shelves that is completely empty.
Healthcare Shares

The ASX 200 company selling everything it makes due to its major competitor being out of the market: fundie

ResMed is performing strongly right now.

Read more »

a young woman props her hand under the face as she pokes her head out from under a luxurious doona in a bedroom decorated with flowers and a stylish lamp.
Healthcare Shares

Resmed share price dips despite profit and dividend boost

Profits and dividends are up, so why is the Resmed share price down?

Read more »

A sad looking scientist sitting and upset about a share price fall.
Earnings Results

Avita share price dives 16% on net loss

The medical technology company's shares are falling following today's financial results

Read more »

A man waking up happy with a smile on his face and arms outstretched representing the hefty Adairs dividend yield
Earnings Results

ResMed share price on watch following solid FY22 growth

ResMed has released its full year results...

Read more »